Compare Amylx Pharmaceuticals Inc (AMLX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 1736.8× 22nd Century Group Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | XXII | |
|---|---|---|
Market Cap | $2.64B | $1.52M |
Sector | Health | Technology |
52-Week High | $24.19 | $801.00 |
52-Week Low | $7.82 | $3.72 |
Enterprise Value | $2.39B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
